seekingalpha.com /2 weeks ago

BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript

Read source
fool.com /1 month ago

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Read source
fool.com /1 month ago

BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?

BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.

Read source
fool.com /1 week ago

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.

Read source
fool.com /1 month ago

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

It has been a volatile year for the biotech.

Read source
investing.com /1 month ago

Bavarian Nordic lifts revenue, margin outlook on U.S. rabies vaccine demand

Read source
qchron.com /3 weeks ago

Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or "Bambusa"), a clinical-stage biopharmaceutical company developing next-ge...

Read source
seekingalpha.com /1 week ago

Blackstone to provide Pfizer up to $1.5B to advance monthly GLP-1 for weight loss

Read source
seekingalpha.com /1 month ago

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Read source
seekingalpha.com /1 month ago

Trump: Becton Dickinson agrees to invest $3B in US manufacturing, including $1B+ in Nebraska

Read source
investing.com /1 month ago

Novo Nordisk licenses Nanexa drug tech in deal worth up to €1.17 bln

Read source
qchron.com /3 weeks ago

BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 29, 2026 /PRNewswire/ --

Read source
qchron.com /1 month ago

BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July...

Read source
investing.com /1 month ago

MeiraGTx chief scientific officer Naylor sells $294,291 in shares

Read source
seekingalpha.com /1 week ago

Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow

Read source
qchron.com /4 weeks ago

BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 24, 2026 /PRNewswire/ --

Read source
seekingalpha.com /1 month ago

Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)

Read source
biopharmadive.com /1 week ago

AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s s...

Read source
fool.com /2 weeks ago

Neurocrine (NBIX) Q3 2026 Earnings Call Transcript

Record $1.1B revenue marks transformative quarter for diversified biotech.

Read source
cafepharma.com /1 week ago

Beigene

Beigene Anonymous (not verified) Tue, 11/10/2026 - 21:36 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Read source
biopharmadive.com /1 month ago

Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first...

Read source
fool.com /1 month ago

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

Read source
investing.com /3 weeks ago

Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data

Read source
newsbtc.com /2 days ago

BingX Adds Anthropic Spot and Perpetual Futures Trading Following Nasdaq Debut

PANAMA CITY, November 19, 2026 – BingX, the world’s leading multi-asset trading platform, today announced that Anthropic (Nasdaq: ANT) is available for trading on its platform foll...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.